Galectin 3 rs4644 gene polymorphism is associated with metabolic traits in Serbian adolescent population
Abstract
Background: Among many genes which have been analyzed to understand obesity and related metabolic traits among children and adolescents, not many studies are conducted on LGALS3 gene, especially in population of children. A positive correlation of circulating galectin 3 serum levels with impaired blood glucose, high blood pressure and higher values of serum lipids and was found in general population. The aim was to investigate possible association of rs4644 with body mass index, glycaemia, and lipid profile in Serbian adolescents.
Methods: The study included 72 boys and 79 girls, 14-15 years of age. Among boys 51 (67.1%) had normal values of BMI, 11 (14.5%) were overweight, and 14 (18.4%) were obese. Among girls, 53 (63.9%) had normal BMI, 16 (19.3%) were overweight, and 14 (16.9%) were obese. Diabetes type 1 or 2, genetic syndromes, generalized inflammation, cardiovascular and malignant diseases were criteria for exclusion. Genotyping was performed by Real time PCR.
Results: Girls carriers of CC genotype had statistically higher mean values of BMI, and triglycerides in comparison to the girls carriers of CA+AA genotypes, p=0.041, and p=0.045, respectively. The higher frequency of obese was found among group of girls who were carriers of CC genotype, p=0.049. No statistically significant association was observed among other analyzed parameters in neither examined groups.
Conclusion: Our research indicates that there is an association between the CC genotype of rs4644 polymorphism with obesity and higher triglycerides level in the group of female adolescents.
References
1. Wang HH, Lee DK, Liu M, Portincasa P, Wang DQH. Novel insights into the pathogenesis and management of the metabolic syndrome. Pediatr Gastroenterol Hepatol Nutr. 2020;23(3):189–230. 10.5223/pghn.2020.23.3.189
2. Bitew ZW, Alemu A, Ayele EG, Tenaw Z, Alebel A, Worku T. Metabolic syndrome among children and adolescents in low and middle income countries: a systematic review and meta-analysis. Diabetol Metab Syndr. 2020;12(1):1–23. 10.1186/s13098-020-00601-8.
3. Sciacchitano S, Lavra L, Morgante A, Ulivieri A, Magi F, De Francesco GP, et al. Galectin-3: One molecule for an alphabet of diseases, from A to Z. Int J Mol Sci. 2018;19(2). 10.3390/ijms19020379
4. Pugliese G, Iacobini C, Pesce CM, Menini S. Galectin-3: An emerging all-out player in metabolic disorders and their complications. Glycobiology. 2015;25(2):136–50. 10.1093/glycob/cwu111
5. Dong R, Zhang M, Hu Q, Zheng S, Soh A, Zheng Y, et al. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). Int J Mol Med. 2018;41(2):599–614. 10.3892/ijmm.2017.3311
6. de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med. 2012;272(1):55–64. 10.1111/j.1365-2796.2011.02476.x
7. Zhen S, Ma Y, Han Y, Zhao Z, Yang X, Wen D. Serum galectin-3BP as a novel marker of obesity and metabolic syndrome in Chinese adolescents. BMJ Open Diabetes Res Care. 2021;9(1):1–8. 10.1136/bmjdrc-2020-001894
8. Blasetti Fantauzzi C, Iacobini C, Menini S, Vitale M, Sorice GP, Mezza T, et al. Galectin-3 gene deletion results in defective adipose tissue maturation and impaired insulin sensitivity and glucose homeostasis. Sci Rep. 2020;10(1):1–15. 10.1038/s41598-020-76952-z
9. Kovacevic Z, Lazarevic T, Maksimovic N, Grk M, Volarevic V, Jankovic MG, et al. Galectin 3 (LGALS3) Gene Polymorphisms Are Associated with Biochemical Parameters and Primary Disease in Patients with End-Stage Renal Disease in Serbian Population. J Clin Med. 2022;11(13):1–11. 0.3390/jcm11133874
10. Yilmaz H, Cakmak M, Inan O, Darcin T, Akcay A. Increased levels of galectin-3 were associated with prediabetes and diabetes: New risk factor? J Endocrinol Invest.2015;38(5):527–33.
11. Majkic-Singh N, Ilic M, Jankovic O, Ignjatovic S, Obradovic I. Trendovi u nalazima lipidnih frakcija u JUSAD studiji. In: Nedeljkovic S, Simeunovic S, Vukotic M, editors. Jugoslovenska studija prekursora ateroskleroze kod skolske dece. Belgrade: Faculty of Medicine, Belgrade University; 2006. p. 529.
12. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215. 10.1093/nar/16.3.121513. Menini S, Iacobini C, Blasetti Fantauzzi C, Pesce CM, Pugliese G. Role of galectin-3 in obesity and impaired glucose homeostasis. Oxid Med Cell Longev. 2016;2016(9618092):1–7. 10.1155/2016/9618092
14. Weigert J, Neumeier M, Wanninger J, Bauer S, Farkas S, Scherer MN, et al. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab. 2010;95(3):1404–11. 10.1210/jc.2009-1619
15. Lin D, Hong X, Sun K, Zhang X, Lian H, Wang J, et al. Galectin-3/adiponectin as a new biological indicator for assessing the risk of type 2 diabetes: a cross-sectional study in a community population. Aging (Albany NY). 2021;13(11):15433–43. 10.18632/aging.203101
16. Ohkura T, Fujioka Y, Nakanishi R, Shiochi H, Sumi K, Yamamoto N, et al. Low serum galectin-3 concentrations are associated with insulin resistance in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2014;6(1):1–7. 10.1186/1758-5996-6-106
17. Atalar MN, Abuşoğlu S, Ünlü A, Tok O, İpekçi SH, Baldane S, et al. Assessment of serum galectin-3, methylated arginine and Hs-CRP levels in type 2 diabetes and prediabetes. Life Sci. 2019;23. 10.1016/j.lfs.2019.116577
18. Liping L, Meilian, L. Adipose tissue in control of metabolism. J Endocrinol.2016; 231(3):
19. Liao YH, Teng MS, Juang JMJ, Chiang FT, Er LK, Wu S, et al. Genetic determinants of circulating galectin-3 levels in patients with coronary artery disease. Mol Genet Genomic Med. 2020;8(9):1–10. 10.1002/mgg3.1370
20. Florido R, Kwak L, Echouffo-Tcheugui JB, Zhang S, Michos ED, Nambi V, et al. Obesity, Galectin-3, and Incident Heart Failure: The ARIC Study. J Am Heart Assoc. 2022;11(9)::e023238.
21. Ibrahim BA, Mohamed SH, Hassaan MMM, Sabbah NA. Associations of galectin-3 expression and lgals-3 (rs4652) gene variant with coronary artery disease risk in diabetics. J Med Biochem. 2021;40(4):395–406. 10.5937/jomb0-30424
22. Kuryłowicz A. Estrogens in Adipose Tissue Physiology and Obesity-Related Dysfunction. Biomedicines.2023; 11(3), 690.10.3390/biomedicines11030690
23. Maksimovic N, Vidovic V, Damnjanovic T, Jekic B, Majkic Singh N, Simeunovic S, et al. Association of PRDM16 rs12409277 and CtBP2 rs1561589 gene polymorphisms with lipid profile of adolescents. Arch Med Sci. 2021;1–7. 10.5114/aoms/113174
24. Vidović V, Maksimović N, Vidović S, Damnjanović T, Novaković I. Association of PPARG rs3856806 C>T polymorphism with body mass index, glycaemia and lipid parameters in Serbian adolescents. Scr Med. 2021;52(1):15–21. 10.5937/scriptamed52-29376
25. Zhang Y, Wang Y, Zhai M, Gan T, Zhao X, Zhang R, et al. Influence of LGALS3 gene polymorphisms on susceptibility and prognosis of dilated cardiomyopathy in a Northern Han Chinese population. Gene. 2018;642:293–8. 10.1016/j.gene.2017.11.026
26. Bobronnikova L. obronnikova L. Galectin-3 as a potential biomarker of metabolic disorders and cardiovascular remodeling in patients with hypertension and type 2 diabetes. Vessel Plus. 2017;1:61–7. 10.20517/2574-1209.2016.10
Copyright (c) 2023 Vanja Vidovic, Ivana Novaković, Tatjana Damnjanović, Žana Radić Savić, Stojko Vidović, Ranko Škrbić, Nela Maksimović
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.